SCHEMBL571063

SCHEMBL571063

COc1ccc(CC(=O)c2ccccc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.69
TP53 P04637 1/20 0.69
NPC1 O15118 3/20 0.63
RAB9A P51151 2/20 0.63
HTT P42858 2/20 0.62
LMNA P02545 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.59
CES2 O00748 1/20 0.59
CES1 P23141 1/20 0.59
KMT2A Q03164 1/20 0.56
ALDH1A1 P00352 2/20 0.55
MAPT P10636 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KDM4E B2RXH2 1/20 0.55
POLB P06746 1/20 0.55
PLAU P00749 1/20 0.55
ELANE P08246 1/20 0.55
CTBP2 P56545 1/20 0.54
STS P08842 1/20 0.54
HSD11B1 P28845 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248073 0.93 NPC1 (0.73) USP2TP53NPC1RAB9AHTT
SCHEMBL457954 0.91 NPC1 (0.73) USP2TP53NPC1RAB9AHTT
SCHEMBL1694670 0.90 NPC1 (0.63) USP2TP53NPC1RAB9AHTT
SCHEMBL10694377 0.88 SRD5A2 (0.68) USP2TP53NPC1RAB9AHTT
SCHEMBL6208174 0.86 L3MBTL1 (0.70) USP2TP53NPC1RAB9AHTT
SCHEMBL1419819 0.86 L3MBTL1 (0.70) USP2TP53NPC1RAB9AHTT
SCHEMBL28438923 0.85 RAB9A (0.61) USP2TP53NPC1RAB9AHTT
SCHEMBL9541930 0.85 SRD5A2 (0.62) USP2TP53L3MBTL1MAPTPLAU
Methoxymethane SCHEMBL27486318 0.85 MAPT (0.63) USP2TP53NPC1RAB9ALMNA
SCHEMBL27572327 0.85 ALDH1A1 (0.63) USP2TP53NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697053-A Biocide composition 巴斯夫欧洲公司 2023-02-03 CN claimed
CN-111170856-B Preparation method and application of fluoroolefin 云南民族大学 2022-04-15 CN claimed
CN-112426884-A Antibacterial composite reverse osmosis membrane and preparation method thereof 嘉兴市爵拓科技有限公司 2021-03-02 CN claimed
US-8815940-B2 Coumarin-chalcones as anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-08-26 US claimed
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 US claimed
EP-2601183-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS Council Of Scientific & Industrial Research (IN) 2013-06-12 EP claimed
WO-2012017454-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-02-09 WO claimed
US-5648159-A Dry resist DIAFOIL HOECHST COMPANY, LTD. (JP) 1997-07-15 US claimed
US-20250002519-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME UNIV YALE (US) 2025-01-02 US disclosed
CN-118006232-B Anti-collision protective film and preparation method thereof 深圳市精恒光电科技有限公司 2024-12-27 CN disclosed
US-20240368001-A1 SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF AQUAFORTUS TECHNOLOGIES LIMITED (NZ) 2024-11-07 US disclosed
US-12071445-B2 Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same YALE UNIVERSITY (US) 2024-08-27 US disclosed
EP-3845546-B1 COMPLEXES JOHNSON MATTHEY PLC (GB) 2024-06-19 EP disclosed
EP-3842421-B1 COMPLEXES JOHNSON MATTHEY PLC (GB) 2024-06-12 EP disclosed
EP-0587670-A1 PCP RECEPTOR LIGANDS AND THE USE THEREOF STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) 1994-03-23 EP disclosed
WO-1992019621-A1 PCP RECEPTOR LIGANDS AND THE USE THEREOF STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE, OREGON (US) 1992-11-12 WO disclosed
EP-0029105-B1 RADIATION CURABLE COATING COMPOSITION, PROCESS FOR COATING A SUBSTRATE THEREWITH, EYEGLASSES AND LAMINATE GAF CORPORATION (US) 1986-02-05 EP disclosed
US-4557996-A Method for providing a pattern-wise photoresist layer on a substrate plate and a surface-protected substrate plate therefor PHOTOPOLY OHKA CO., LTD. (JP) 1985-12-10 US disclosed
US-4319811-A OF TRIACRYLATES AND N-BINYL IMIDO GROUP GAF CORPORATION (US) 1982-03-16 US disclosed
EP-0029105-A2 Radiation curable coating composition, process for coating a substrate therewith, eyeglasses and laminate GAF CORPORATION (US) 1981-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002519-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME TIMCC, YAP1, TET2 USP2 1344/4885TP53 258/4885NPC1 4247/4885
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS HCCS, XPO5, CIAPIN1 USP2 4651/4885TP53 43/4885NPC1 148/4885
US-12071445-B2 Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same TIMCC, YAP1, TET2 USP2 1566/4885TP53 177/4885NPC1 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.